NCT02892123 2024-11-27Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing CancersJazz PharmaceuticalsPhase 1 Completed279 enrolled
NCT03424473 2020-02-25Expanded Access Use of Tucatinib for HER2+ Metastatic Breast CancerSeagen Inc.No longer available